Search research articles
Contact Us
Filters
Showing results (81-90 of 112) with videos related to
Page
of 12
Sort By:
Cell Transplantation
|
April 28, 2000
The risks of total pancreatectomy and splenic islet autotransplantation
S A White, N J London, P R Johnson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 11, 2008
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
A Palumbo, F Gay, S Bringhen, et al.
Leukemia
|
October 31, 2003
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2))
A Palumbo, S Bringhen, A Bertola, et al.
Endoscopy
|
January 27, 2010
A prospective study comparing rapid assessment of smears and ThinPrep for endoscopic ultrasound-guided fine-needle aspirates
J K LeBlanc, R E Emerson, J Dewitt, et al.
Pancreas
|
September 26, 2008
Islet auto transplantation following total pancreatectomy: a long-term assessment of graft function
M'Balu A Webb, Severine C Illouz, Cristina A Pollard, et al.
International Journal of Immunopathology and Pharmacology
|
January 11, 2012
Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis
G D'Arena, G Rossi, M M Minervini, et al.
Haematologica
|
May 9, 2000
Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients
A Palumbo, S Triolo, L Baldini, et al.
Leukemia Research Reports
|
July 21, 2025
Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of "Rete Ematologica Pugliese" (REP)
M Dargenio, C Buquicchio, D Pastore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 1, 2011
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party
G D'Arena, C G Valentini, G Pietrantuono, et al.
Annals of Hematology
|
May 19, 2022
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'
G Mele, N Cascavilla, N Di Renzo, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 112) with videos related to
Sort By:
Page
of 12
Cell Transplantation
|
April 28, 2000
The risks of total pancreatectomy and splenic islet autotransplantation
S A White, N J London, P R Johnson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 11, 2008
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
A Palumbo, F Gay, S Bringhen, et al.
Leukemia
|
October 31, 2003
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2))
A Palumbo, S Bringhen, A Bertola, et al.
Endoscopy
|
January 27, 2010
A prospective study comparing rapid assessment of smears and ThinPrep for endoscopic ultrasound-guided fine-needle aspirates
J K LeBlanc, R E Emerson, J Dewitt, et al.
Pancreas
|
September 26, 2008
Islet auto transplantation following total pancreatectomy: a long-term assessment of graft function
M'Balu A Webb, Severine C Illouz, Cristina A Pollard, et al.
International Journal of Immunopathology and Pharmacology
|
January 11, 2012
Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis
G D'Arena, G Rossi, M M Minervini, et al.
Haematologica
|
May 9, 2000
Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients
A Palumbo, S Triolo, L Baldini, et al.
Leukemia Research Reports
|
July 21, 2025
Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of "Rete Ematologica Pugliese" (REP)
M Dargenio, C Buquicchio, D Pastore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 1, 2011
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party
G D'Arena, C G Valentini, G Pietrantuono, et al.
Annals of Hematology
|
May 19, 2022
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'
G Mele, N Cascavilla, N Di Renzo, et al.
Page
of 12